Free Newsletter
Merck KGaA CEO eyes new acquisitions
Merck KGaA is thinking big...bigger...and even bigger. The company's new chairman, Karl Ludwig Kley (photo), says he's planning a series of acquisitions over the next three years to grow its consumer health and life sciences businesses, all while expanding its pharma and liquid crystal divisions from within. The aim: $13.9 billion in sales by 2010.
That's no chump change, and it'll take several billions' worth of acquisitions to get there. But challenging or no, it's a focused strategy, which is more than Merck KGaA has had over the past couple of years, given the exit of Kley's predecessor, the sell-off of the company's generics division, and its buyout of the Swiss biotech Serono.
- read this article in the Financial Times
Related Articles:
Mylan inks $6.6B deal for Merck's generic drug biz. Report
Merck KGaA buying control of Serono. Report
Bayer outbids Merck KGaA for Schering. Report
Gene Logic takes fresh look at Merck KGaA drugs. Report
The Top 5 Buyouts of 2007. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: